Wegovy and Sight Loss: What the Clinical Evidence Actually Shows

You read the headline about Wegovy and vision — here is what actually happened in the research

In June 2024 a retrospective study published in JAMA Ophthalmology looked at medical records from a US academic centre and found that people prescribed semaglutide for type 2 diabetes had a statistically higher rate of NAION compared with those on other diabetes medicines. NAION is a condition where blood flow to the optic nerve is suddenly reduced, causing painless but often permanent loss of part of the visual field. It is rare in the general population but more common in people with diabetes, hypertension, or pre-existing optic nerve anatomy that makes them structurally vulnerable.

The study found roughly 8 cases per 10,000 people in the semaglutide group compared with about 2 per 10,000 in those on other medications. That fourfold difference sounds alarming in isolation. It becomes less clear-cut once you account for the study's limitations: it was observational rather than a randomised trial, the numbers involved were small in absolute terms, the researchers could not fully control for how sick the two groups were at baseline, and the association was not replicated with comparable strength in the weight-management population (where Ozempic and Wegovy are used quite differently). The NHS's guidance on semaglutide notes vision-related side effects as something to discuss with a clinician, and the NHS medicines page for semaglutide advises contacting a doctor promptly for any sudden changes in eyesight.

The JAMA paper does not confirm that semaglutide causes NAION. It identifies a signal that warrants further investigation. That distinction matters enormously when you are trying to decide whether the risk profile of this medicine makes sense for you personally.

Why the diabetes-related eye-disease context changes how you read the data

Diabetic retinopathy affects the blood vessels inside the eye, and people who already have background retinopathy may experience a temporary worsening of their eye condition when blood glucose drops quickly, particularly at the start of diabetes treatment. This phenomenon, sometimes called early worsening, has been observed with GLP-1 medicines in clinical trials including the SUSTAIN-6 cardiovascular outcomes trial for semaglutide. It is recognised in prescribing guidance and tends to stabilise as glucose levels settle.

NAION is a separate condition with different anatomy, but the overlap is relevant: the population most at risk of NAION overlaps significantly with the population most likely to be using semaglutide for diabetes. Unpicking cause from correlation in that setting is genuinely difficult, even for well-designed studies. If you are considering Wegovy specifically for weight loss and you do not have diabetes or pre-existing optic nerve pathology, the available evidence does not currently suggest an elevated personal risk, though that picture may be refined as larger, prospective data emerge.

Our clinical team at nume reviews each person's medical history in full before any prescription is issued. Someone with a history of eye disease, optic nerve pathology, or prior NAION episodes would have that factored explicitly into the prescribing decision.

What regulators have said, and what that means for your prescription

As of summer 2026, the MHRA has not issued a specific Drug Safety Update restricting or contraindicting semaglutide on NAION grounds. The evidence remains under active review by regulators worldwide. The European Medicines Agency initiated a review following the 2024 paper, and the FDA has required label updates in the United States to reflect the signal. In the UK, any changes to prescribing guidance would be communicated via the MHRA's Drug Safety Update series, which is the appropriate place to check for the latest position.

This is one of those situations where the right answer genuinely is: talk to your prescriber. A question our prescribers hear regularly is whether a past eye condition should rule out semaglutide entirely. The answer is nearly always nuanced: it depends on the specific condition, its severity, and your overall risk profile. The related question of Wegovy and eyesight more broadly covers the range of visual side effects documented in trials, which is worth reading alongside this page.

If you are already on treatment and want to understand how much weight loss to expect or how long it takes to see results, the timeline of Wegovy weight loss covers the realistic trajectory in detail, and if the scales have not shifted after your first few weeks it is worth reading about why three weeks on Wegovy with no weight loss is more common than people expect. The semaglutide overview sets out everything that is licensed and known about the medicine itself.

When to seek urgent help, and what counts as an emergency

This section matters most. NAION typically presents as sudden, painless loss of vision in one eye, often noticed first thing in the morning (the sort of moment you might glance at your phone before the kettle has boiled and realise something is wrong). It can affect the whole visual field or appear as a greyness or blurring in one section of your sight. It is not the same as the mild visual blurring some people notice during rapid blood-sugar shifts.

If you experience any of the following while taking Wegovy or any other GLP-1 medicine, seek same-day urgent medical assessment, not a routine GP phone appointment: sudden loss of vision in one or both eyes; a dark patch, shadow or missing area in your visual field; sudden onset of double vision; any eye pain accompanied by vision change. These are potential signs of a serious vascular event and time matters. Do not drive yourself to hospital if your vision is significantly affected.

You can also report any suspected side effect to the MHRA via the Yellow Card scheme, which is how post-market safety signals like this one are gathered and reviewed. Reporting matters, even if it turns out to be unrelated to the medicine.

For anyone weighing up whether Wegovy is right for them in light of this evidence, a free consultation with a GPhC-registered prescriber is the sensible first step. You can explore the full range of weight-loss treatments we offer at nume, or start your free consultation today so a real clinician can review your history and give you a straight answer.